<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02785822</url>
  </required_header>
  <id_info>
    <org_study_id>IIBSP-FOS-2016-01</org_study_id>
    <nct_id>NCT02785822</nct_id>
  </id_info>
  <brief_title>Study to Compare hFSH-HP (Fostipur) and hMG-HP(Meriofert) in Patients With Polycystic Ovary Under a IVF/ICSI Cycle.</brief_title>
  <official_title>Randomized, Single Blind, Prospective Clinical Study to Compare hFSH-HP (Fostipur) and hMG-HP(Meriofert) in Patients With Polycystic Ovary Under a IVF/ICSI Cycle.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Programa de Reproducción Asistida F. Puigvert - HSCSP</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Polycystic ovary occurs in 15-20% of the population will be submitted to TRA. Whether it is
      associated with other signs or symptoms (polycystic ovarian syndrome) as if presented in
      isolation, its therapeutic management has special connotations sometimes favoring the low
      response although the standard is the tendency to hyperresponsiveness.

      Although there are studies comparing the combination of FSH and LH and FSH in controlled
      hyperstimulation of these patients, there are no previous prospective randomized studies
      comparing administration of urinary FSH (hFSH-HP) with a combination of FSH and HCG (HMG HP).

      Therefore the aim of this study is to prove that both drugs are comparable in the treatment
      of these patients. The test substances are marketed in Spain (Fostipur and Meriofert,
      respectively) with an indication for use in these patients. In this study both medicines will
      be administered in a randomized way under the usual conditions in which it is used in routine
      clinical practice to compare the quantity of mature oocytes respect to the total oocytes
      obtained, as a primary outcome measure.
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">June 1, 2018</start_date>
  <completion_date type="Anticipated">June 2019</completion_date>
  <primary_completion_date type="Anticipated">June 2019</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Quantity of mature oocytes respect to the total oocytes</measure>
    <time_frame>30 days</time_frame>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">164</enrollment>
  <condition>Polycystic Ovary Syndrome</condition>
  <arm_group>
    <arm_group_label>Fostipur</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Meriofert</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>hMG-HP</intervention_name>
    <description>Ovarian stimulation with hMG-HP (150 IU / day)</description>
    <arm_group_label>Meriofert</arm_group_label>
    <other_name>Meriofert</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>hFSH-HP</intervention_name>
    <description>Ovarian stimulation with hFSH-HP (150 IU / day)</description>
    <arm_group_label>Fostipur</arm_group_label>
    <other_name>Fostipur</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Female age between 18 and 38 years (inclusive)

          -  Women with a BMI under 30 kg / m2

          -  Diagnosis of polycystic ovary syndrome (according to criteria of Rotterdam)

          -  Women who want pregnancy

          -  Basal basal FSH levels under or equal 10 IU / l

          -  Infertility justify treatment with in vitro fertilization / intracytoplasmic sperm
             injection

          -  To be included in a protocol with GnRH antagonist

          -  Presence of both ovaries and uterus able to support embryo implantation and pregnancy

          -  Absence of pregnancy before starting ovarian stimulation

          -  Written consent

        Exclusion Criteria:

          -  Severe male factor not allowing an in vitro fertilization / intracytoplasmic sperm
             injection with ejaculated sample

          -  Patients with low ovarian reserve

          -  Important endocrine-metabolic systemic diseases affecting pituitary, thyroid,
             adrenals, pancreas, liver or kidney

          -  HIV seropositivity

          -  To have frozen embryos from previous cycles of assisted reproduction

          -  Undiagnosed vaginal haemorrhage

          -  Poor response in previous cycles of in vitro fertilization with standard stimulation
             protocols

          -  Pregnancy, lactation or contraindication to get pregnant

          -  Malformations of the sexual organs incompatible with pregnancy

          -  History of allergy to gonadotrophin preparations or its excipients

          -  Alcohol, drugs or psychotropic addiction

          -  Concurrent participation in another study

          -  Previous history of severe hyperstimulation syndrome

          -  Concomitant medication that may interfere with the study medication: different
             hormonal treatments used in the study, other thyroid hormones, antipsychotics,
             anxiolytics, hypnotics, sedatives, chronic treatment with inhibitors of prostaglandin
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>38 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Juan J Espinos, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Juan J Espinos, MD</last_name>
    <phone>+34935537613</phone>
    <email>jespinos@santpau.cat</email>
  </overall_contact>
  <location>
    <facility>
      <name>Fundació Puigvert</name>
      <address>
        <city>Barcelona</city>
        <zip>08025</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Pere Pares, MD</last_name>
    </contact>
    <investigator>
      <last_name>Pere Pares, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital de la Santa Creu i Sant Pau</name>
      <address>
        <city>Barcelona</city>
        <zip>08026</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Juan J Espinos, MD</last_name>
    </contact>
  </location>
  <location_countries>
    <country>Spain</country>
  </location_countries>
  <verification_date>May 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 25, 2016</study_first_submitted>
  <study_first_submitted_qc>May 27, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 30, 2016</study_first_posted>
  <last_update_submitted>May 10, 2018</last_update_submitted>
  <last_update_submitted_qc>May 10, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">May 16, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Reproductive Techniques, Assisted</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Polycystic Ovary Syndrome</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

